On the welfare analysis of external reference pricing and reimbursement policy

被引：0
|
作者：
Dong, Van-Chung [1 ,2 ]
Lin, Yan-Shu [1 ]
Shih, Pei-Cyuan [3 ]
机构：
[1] Natl Dong Hwa Univ, Dept Econ, Hualien, Taiwan
[2] Vietnam Acad Social Sci, Hanoi, Vietnam
[3] Ming Chuan Univ, Dept Int Business, Taipei, Taiwan
来源：
ESTUDIOS DE ECONOMIA | 2023年 / 50卷 / 01期
关键词：
Copayment rate; direct and indirect sales channeles; external refe-rence pricing; reimbursement policy; PHARMACEUTICAL POLICY;
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
The co-existence of external referencing pricing (ERP) and reimbursement policy is common in many countries. Thus, this research examines whether or not the imposition of ERP is socially desirable in the presence of reimbursement policy. For direct sales channel, we find that the home social welfare is worse-off with ERP if the home copayment rate is too high. Our main results are robust under indirect sales channel. Moreover, the home social welfare under the pharmacy-purchasing-price (PPP) ERP is larger than that under the ex-factory-price (EFP) ERP if the home copayment rate is high enough. Finally, the profit of brand-name firm under indirect sales channel is higher than that under direct sales channel if the home copayment rate is too high.
引用
收藏
页码：133 / 158
页数：26
相关论文
共 50 条
  • [1] External Reference Pricing and Parallel Imports of Pharmaceuticals: A Policy Comparison
    Iravani, Foad
    Mamani, Hamed
    Nategh, Emisa
    [J]. PRODUCTION AND OPERATIONS MANAGEMENT, 2020, 29 (12) : 2716 - 2735
  • [2] PRICING AND REIMBURSEMENT POLICY UPDATES IN ASIA
    Paranjoy, S.
    Kaushik, P.
    Kaur, S.
    Sharma, S.
    Sehgal, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A788 - A788
  • [3] The 1996 pricing and reimbursement policy in the Netherlands
    deVos, CM
    [J]. PHARMACOECONOMICS, 1996, 10 : 75 - 80
  • [4] PHARMACEUTICAL SYSTEM IN UKRAINE: IMPLEMENTATION OF EXTERNAL REFERENCE PRICING, REIMBURSEMENT PROGRAMS AND HEALTH TECHNOLOGY ASSESSMENT
    Piniazhko, O.
    Zaliska, O.
    Ilyk, R.
    Stasiv, Kh-O
    [J]. PHARMACIA, 2018, 65 (02) : 28 - 39
  • [5] Variations in external reference pricing implementation: does it matter for public policy?
    Jennifer Gill
    Anna-Maria Fontrier
    Dionysis Kyriopoulos
    Panos Kanavos
    [J]. The European Journal of Health Economics, 2019, 20 : 1375 - 1397
  • [6] Variations in external reference pricing implementation: does it matter for public policy?
    Gill, Jennifer
    Fontrier, Anna-Maria
    Kyriopoulos, Dionysis
    Kanavos, Panos
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (09): : 1375 - 1397
  • [7] Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications
    Incze, Andras
    Kalo, Zoltan
    Espin, Jaime
    Kiss, Eva
    Kessabi, Sophia
    Garrison, Louis P.
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] A MODEL SIMULATING EXTERNAL REFERENCE PRICING TO SUPPORT POLICY DECISION MAKING IN EUROPE
    Vataire, A. L.
    Cetinsoy, L.
    Remuzat, C.
    Aballea, S.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A192 - A192
  • [9] DRUG POLICY IN SLOVAKIA: IMPACT OF PRICING AND REIMBURSEMENT REFORMS
    Glatz, P.
    Ilavska, A.
    Hloska, A.
    Filko, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A95 - A95
  • [10] Results of reference pricing and reimbursement discount rate schemes of Turkey
    Kockaya, Guvenc
    Atikeler, Kagan
    Tuna, Esin
    Kilic, Pelin
    Tanyeri, Pelin
    Umman, Nurcan
    Vural, Ismail Mert
    Altun, Omer
    Akbulat, Akif
    Artiran, Guven
    Simsek, Ercan
    Gursoz, Hakki
    Kerman, Saim
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2013, 14 (02) : 99 - 103
12345